Hearing's Fallen Leader

Hearing's Fallen Leader

Sonova is the world's largest maker of hearing aids — a Swiss blue-chip that reached roughly CHF 402 in late 2021 on market data and now trades at little more than half that. Sales have stalled around CHF 3.6 billion, operating margins have fallen from 22.6% to 18.7%, and a four-year push into consumer audio is being unwound at a loss. The balance sheet is strong; the growth story is the open question.

What Sonova is

Sonova Holding AG designs, makes and sells hearing solutions under four brands — Phonak and Unitron (prescription hearing aids), Advanced Bionics (cochlear implants), and, until recently, Sennheiser-branded consumer audio (under license) [1]. It runs both sides of the value chain: it manufactures the devices and operates one of the world's largest retail networks of hearing-care stores (AudioNova and other banners) that fit them [2]. The company was founded as Phonak in 1947, has traded on the SIX Swiss Exchange since 1994, and is a constituent of the blue-chip SMI index.

The business reports in two segments. Hearing Instruments — the prescription wholesale devices plus the retail store network — is the engine, at CHF 3,353.8 million of external sales in fiscal 2025/26 [3]. Cochlear Implants — surgically implanted devices for severe-to-profound loss — is the small, higher-tech second leg at CHF 252.1 million, and it is currently shrinking [4]. The company's fiscal year ends 31 March; "FY2026" here means the year ended 31 March 2026.

Sources: share price and drawdown from market data (a late-2021 peak of ~CHF 402; the filings anchor a CHF 387.60 close at 31 Mar 2022, implying a ~46–48% drawdown); sales and EPS from FY2025/26 consolidated income statement [5].

At CHF 209 the company is worth roughly CHF 12.5 billion — a mid-to-large-cap by Swiss standards, and no longer the premium-rated compounder it was four years ago.

Why the market re-rated it

The demand backdrop is one of the most durable in healthcare. About 1.5 billion people — a fifth of the world's population — live with some degree of hearing loss, and roughly 430 million have moderate-or-worse loss, a number that rises as populations age; most of them go untreated [6]. A leader in a low-penetration, demographically tailwinded market is exactly the kind of franchise that earns a premium multiple — which is what Sonova had, until it didn't.

Four things turned the story. Growth normalized after a post-pandemic surge (sales grew 29% in FY2022, then went sideways). Margins compressed. A diversification bet failed. And a technology fear arrived.

Source: FY2025/26 Annual Report, Five Year Key Figures — restated to continuing operations [7].

Revenue has been essentially flat for four years while operating profit has drifted lower. The clearer signal is the margin: EBIT margin fell from 22.6% in FY2022 to 18.7% in FY2026, a step-down of nearly four points that has never fully recovered.

Source: FY2025/26 Annual Report, Five Year Key Figures [8].

Gross margin has actually held above 73%, so the erosion is below the gross line — in operating cost, particularly sales-and-marketing intensity that climbed as growth slowed. Whether that compression is cyclical or structural is one of the report's central threads.

The Sennheiser round-trip

In March 2022 Sonova bought Sennheiser's consumer audio division to push into "hearables" and reach consumers earlier in their hearing journey — a hedge against the fear that consumer electronics would encroach on hearing care [9]. Four years later, on 23 March 2026, management announced it would sell the business back out, booking a CHF 38.3 million pre-tax impairment and classifying Consumer Hearing as discontinued operations [10]. The unit lost CHF 106.5 million after tax in FY2026, which is why reported earnings per share fell to CHF 7.23 even as continuing operations earned CHF 9.02 [11].

The technology fear it was meant to answer became concrete in September 2024, when U.S. regulators cleared software turning Apple's AirPods Pro into an over-the-counter hearing aid. Hearing-aid stocks slid on the news; sell-side analysts argued the OTC market targets a different, milder-loss population than Sonova's prescription base. The debate over whether Apple and OTC devices commoditize the core franchise — or merely widen the funnel into it — is unresolved and belongs to a later chapter.

A strong balance sheet, and no founder

For an investor who wants the probability of ruin near zero, Sonova is reassuring. Net debt was CHF 994.3 million at 31 March 2026 — roughly 1.2 times normalized operating profit before amortization — and it has fallen every year since FY2023 [12]. The dividend was raised through the entire de-rating, from CHF 4.40 to a proposed CHF 4.70 per share [13]. Bankruptcy is not the risk here.

Source: FY2025/26 Annual Report, Five Year Key Figures — restated to continuing operations [14].

What Sonova is not is founder-run. Its board is entirely non-executive and independent, with no controlling shareholder [15], and the company changed both its chief executive — Arnd Kaldowski to Eric Bernard, who took over in September 2025 — and its chairman during 2025 [16]. Skin in the game runs low: this is professionally managed, widely held Swiss equity, not an owner-operator with a large personal stake. For an investor who prizes aligned insiders, that is a genuine gap in the fit — one that management compensation and ownership deserve their own examination.

What management now promises, and what the market pays for it

Alongside the divestment, management set a fresh ambition: CHF 6 billion of revenue by FY2030/31, up from CHF 3.6 billion today, built on a re-focused hearing-care portfolio [17]. Consensus is more restrained but still points up: analysts model earnings per share recovering to roughly CHF 10.4 in FY2026/27 and CHF 11.4 in FY2027/28, back above the FY2023 peak. At CHF 209, the shares change hands near 20 times that forward number and yield about 2.2% — cheaper than the 30-plus multiple of the boom years, but not the deep-value price of a broken business.

That framing sets up the question this report is built to answer.

Everything that follows tests one side of that question or the other: whether the margin step-down reverses, whether the moat holds against OTC and Apple, whether capital allocation and incentives are trustworthy, and what a demanding margin of safety would require the price to be.